Pulmonary tuberculosis in hiv-infected patients in zaire – a controlled trial of treatment for either 6 or 12 months

New England Journal of Medicine

Volumn 332, Issue 12, 1995, Pages 779-785

  Perriëns, Joseph H ^a,b   Louis, Michael E ^a   Mukadi, Yiadiul B ^c   Brown, Christopher ^c   Prignot, Jacques ^d   Pouthier, Françoise ^c,d   Portaels, Françoise ^e   Willame, Jean Claude ^e   Mandala, Justin K ^f   Kaboto, Mulamba ^f   Ryder, Robert W ^g   Roscigno, Giorgio ^g   Piot, Peter ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Belgian Agency for Development and Cooperation ^*  (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e Bureau National de la Tuberculose ^*  (Belgium)

^f Centre de Dépistage de la Tuberculose ^*  (Belgium)

^g Marion Merrell Dow Research Institute ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BACTERIUM CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOCRATIC REPUBLIC CONGO; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK ASSESSMENT; SURVIVAL RATE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTICS, ANTITUBERCULAR; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 0028922860     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199503233321204     Document Type: Article

References (29)

1. Diagnosis and management of mycobacterial infection and disease in persons with human T-lymphotropic virus type III/lymphadenopathy-associated virus infection MMWR Morb Mortal Wkly Rep 1986; 35: 448-452
2. Snider DE Jr., Rogowski J, Zierski M, Bek E, Long MW Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland. Am Rev Respir Dis 1982; 125: 265-267
3. Snider DE, Graczyck J, Bek E, Rogowski J Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis 1984; 130: 1091-1094.
4. Singapore Tuberculosis Service, British Medical Research Council. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1988; 137: 1147-1150.
5. Hong Kong Chest Service, British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987; 136: 1339-1342.
6. Klausner JD, Ryder RW, Baende E, Mycobacterium tuberculosis in household contacts of human immunodeficiency virus type 1-seropositive patients with active pulmonary tuberculosis in Kinshasa, Zaire. J Infect Dis 1993; 168: 106-111 [Erratum, J Infect Dis 1993;168:802.]
7. Mukadi Y, Perriëns J, Willame JC, et al. HIV seroprevalence among new cases of pulmonary tuberculosis stable between 1987 and 1989 in Kinshasa, Zaire. In: Abstracts of the Sixth International Conference on AIDS, San Francisco, June 20–24, 1990. Vol. 2. San Francisco: University of California, 1990:233. abstract.
8. Piot P, Laga M, Ryder R, The global epidemiology of HIV infection: continuity, heterogeneity, and change. J Acquir Immune Defic Syndr 1990; 3: 403-412
9. Mukadi Y, Perriens JH, St Louis ME, Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire. Lancet 1993; 342: 143-146
10. Jenkins PA, Pattyn SR, Portaels F. Diagnostic bacteriology. In: Ratledge C, Stanford jC, eds. The biology of the mycobacteria: physiology, identification and classification. Vol. 1. London: Academic Press, 1982:441-70.
11. Canetti G, Froman S, Grosset J, Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29: 565-578
12. Hopewell P, Cynamon M, Starke J, Iseman M, O'Brien R Evaluation of new anti-infective drugs for the treatment and prevention of tuberculosis. Clin Infect Dis 1992; 15: Suppl 1: S282-S295
13. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991; 324: 289-294
14. Okwera A, Whalen C, Byekwaso F, Randomized trial of thiacetazone and rifampicin containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 1994; 344: 1323-1328.
15. European Tuberculosis Treatment Group, ENTA, EEC-Tuberculosis Concerted Actions. Tuberculosis in HIV-infected patients: a multicentric comparative study of a three- versus a four-drug regimen. In: Abstracts of the Ninth International Conference on AIDS/Fourth STD World Congress, Berlin, Germany, June 6–11, 1993. London: Wellcome Foundation, 1993:339. abstract.
16. Gonzalez Montaner LJ, Mosca C, Abbate E, Musella RM, Castagnino JP Treatment of tuberculosis (TB) in patients with AIDS and intravenous drug abusers (IVDA) in Buenos Aires (Argentina). Am Rev Respir Dis 1992; 145: A107-A107 abstract.
17. Lahart CJ, Wood DG, Peacock AL, Wray NP. Tolerance of tuberculous therapy and prophylaxis in HIV infected patients. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Calif., October 10–14, 1992. Washington, D.C.: American Society for Microbiology, 1992:157. abstract.
18. Zamora L, Gatell JM, Mallolas J, et al. Treatment of tuberculosis in HIV infected patients. In: Abstracts of the Sixth International Conference on AIDS, San Francisco, June 20–24, 1990. Vol. 1. San Francisco: University of California, 1990:249. abstract.
19. Combs DL, O'Brien RJ, Geiter LJ USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability: the report of final results. Ann Intern Med 1990; 112: 397-406
20. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed and cost-effective regimen. Ann Intern Med 1990; 112: 407-415
21. Hong Kong Chest Service, British medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: results at 30 months. Am Rev Respir Dis 1991; 143: 700-706
22. Castelo A, Jardim JRB, Goihman S, Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis. Lancet 1989; 2: 1173-1176.
23. Canueto J, Torres TM, Escribano JC, et al. Follow-up of AIDS patients with tuberculosis after completion of anti-tuberculosis therapy: is indefinite therapy advisable? In: Abstracts of the Eighth International conference on AIDS/Third STD World Congress, Amsterdam, July 19–24, 1992. Vol. 2. Amsterdam: CONGREX, 1992:B103. abstract.
24. Kassim S, Sassan-morokro M, Doorly R, et al. Prospective study of pulmonary tuberculosis and HIV-1 and HIV-2 infections, Abidjan, Cote d'Ivoire. In: Abstracts of the Eighth International Conference on AIDS/Third STD World Congress, Amsterdam, July 19–24, 1992. Vol. 2. Amsterdam: CONGREX, 1992:B101.
25. Carton JA, Cárcaba V, Maradona JA, et al. Successful antituberculosis treatment with various drug regimens in patients with HIV infection. In: Proceedings of the Fifth International Conference on AIDS, Montreal, June 4–9, 1989. Ottawa, Ont.: International Development Research Centre, 1989:594. abstract.
26. Perriens JH, Colebunders RL, Karahunga C, Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with “standard“ chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991; 144: 750-755
27. Hawken M, Nunn P, Gathua S, Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 1993; 342: 332-337
28. Nunn P, Brindle R, Carpenter L, Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (6-month) mortality. Am Rev Respir Dis 1992; 146: 849-854
29. colebunders R, Mann JM, Francis H, Generalized papular pruritic eruption in African AIDS patients with human immunodeficiency virus infection. AIDS 1987; 2: 117-121